Experience of British Biotechnology Achievements Transformation and Suggestions

China Biotechnology

2012, Vol. 32

Issue (09): 131-134 DOI:

Experience of British Biotechnology Achievements Transformation and Suggestions

ZHANG Da-lu

China National Center for Biotechnology Development

Download:

HTML

PDF(479KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract As the second strongest country, UK is taking leading role in biotechnology development around world. UK government supported biotechnology in many ways, such as government policy, tax policy and government investments.We tried to review the policies and experiences since 1950’s, the British Government guidance, input as well as a range of incubation policy, contributed to the achievements of the British biotechnology industry.Considering UK's experiences on biotechnology area, is to make reference to Chinese biotechnology development in the future.

Key words： United Kingdom Biotechnology Transformation Suggestion

Received: 09 April 2012 Published: 25 September 2012

ZTFLH:

Q819

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Da-lu

Cite this article:

ZHANG Da-lu. Experience of British Biotechnology Achievements Transformation and Suggestions. China Biotechnology, 2012, 32(09): 131-134.

URL:

https://manu60.magtech.com.cn/biotech/ OR https://manu60.magtech.com.cn/biotech/Y2012/V32/I09/131

[1] 赵清华,范明杰,李玉洁,等. 英国:10%的GDP受益于生物技术应用. 中国生物工程杂志,2008, 28(7):2-5. Zhao Q H, Fan M J, Li Y J, United Kingdom:10 percent of GDP to benefit from biotechnology applications. China Biotechnology, 2008, 28 (7):2-5.
[2] Geoffrey O. Entrepreneurship in UK biotechnology: the role of public policy. The Diebold Institute Entrepreneurship and Public Policy Project,2001,14:6-28.
[3] Charlotte B. How and when did we get here? an historical institutionalist analysis of EU biotechnology policy. Journal of European Integration, 2011, 34(4):341-357
[4] 李志军. 英国技术集团(BTG)的技术转移. 调查研究报告,2003,52: 1-17. Li Z J. British Technology Group (BTG) technology transfer. Research Reports, 2003,52: 1-17.
[5] 孟胜利. 英国生物技术产业的最新进展. 生物技术世界, 2008,6:5-9. Meng S L. The latest progress of the British biotechnology industry. The World of Biotechnology, 2008,6:5-9.
[6] Henderson R, Orsenigo L, Pisano G. The Pharmaceutical Industry and the Revolution in Molecular Biology: Exploring the Interactions Between Scientific, Institutional and Organizational Change in The Sources of Industrial Advantages. Cambridge: Cambridge University Press, 1999. 10-18, 24-35, 52-68.
[7] Calin Gurau, Leo-Paul Dana, el al. Academic entrepreneurship in UK biotechnology firms: alternative models and the associated performance. Journal of Enterprising Communities: People and Places in the Global Economy, 2012,6(2):154-168.
[8] Cockburn I, Henderson R. Public-private interaction in pharmaceutical research. Proc Natl Acad Sci USA, 1996, 93:12725-12730.
[9] Goldman M. Industrial biotechnology in the UK: a funder’s perspective Goldman Merlin. Industrial Biotechnology, 2011, 7(4): 269-271.

[1]	LIU Xu-xia,YANG An-ke. An Analysis of the U.S. SECURE Rule and Its Enlightenment to China[J]. China Biotechnology, 2021, 41(9): 126-135.

[2]	ZHANG Heng,LIU Hui-yan,PAN Lin,WANG Hong-yan,LI Xiao-fang,WANG Tong,FANG Hai-tian. Research Strategy for Biosynthesis of Gamma Aminobutyric Acid[J]. China Biotechnology, 2021, 41(8): 110-119.

[3]	HU Yuan-lei,CHEN Yan-cheng,PU Run,YAO Wei-hao,ZHANG Hong-xiang. Bio-tech Startup Incubation Best Practice in the United Kingdom and Suggestion[J]. China Biotechnology, 2021, 41(4): 100-105.

[4]	WANG Yi-han,LI Hai-yan,XUE Yong-chang. The Structural Characteristics and Engineering Reconstruction of Flavin-dependent Halogenase[J]. China Biotechnology, 2021, 41(4): 74-80.

[5]	WU Han-rong,WANG Ying,HUANG Ying-ming,LI Dong-xue,LI Zhi-fei,FANG Zi-han,FAN Lin. Promote the Innovation and Transformation of Biotechnology by Base Platform[J]. China Biotechnology, 2021, 41(12): 141-147.

[6]	HE Wei,ZHU Lei,LIU Xin-ze,AN Xue-li,WAN Xiang-yuan. Research Progress on Maize Genetic Transformation and Commercial Development of Transgenic Maize[J]. China Biotechnology, 2021, 41(12): 13-23.

[7]	WU Han-rong,WANG Ying,YANG Li,GE Yao,FAN Ling. Current Situation and Development Suggestions of China’s Biotechnology Base Platform[J]. China Biotechnology, 2021, 41(11): 119-123.

[8]	WU Han-rong,WANG Ying,LI Su-ning,SANG Xiao-dong,FAN Ling. Policy Research on the Construction of Biotechnology Base Platforms in China[J]. China Biotechnology, 2021, 41(10): 127-131.

[9]	WANG Xiao-li. The Age of Biosecurity: New Biotechnology Revolution and National Biosecurity Governance[J]. China Biotechnology, 2020, 40(9): 95-109.

[10]	MENG Xiao-lin,PANG Xi-ming,WANG Jie. **Agrobacterium-mediated Transformation and the Functions of Pks in Marine-derived Penicillium oxalicum**[J]. China Biotechnology, 2020, 40(9): 11-17.

[11]	SONG Yi-mei,JIA Xiu-wei,LI Shu-biao,GAO Cui-juan. *Industrial Microorganism of Yarrowia lipolytica* and Its Industrial Amplicaiton**[J]. China Biotechnology, 2020, 40(9): 77-86.

[12]	YANG Li,SHI Xiao-yu,LI Wen-lei,LI Jian,XU Han-mei. Optimization of Electroporation Conditions in Construction of Phage Display Antibody Library[J]. China Biotechnology, 2020, 40(4): 42-48.

[13]	HU Yuan-lei,YAO Wei-hao,PU Run,ZHANG Hong-xiang. Bio-tech Startup Incubation Best Practice in the United States[J]. China Biotechnology, 2019, 39(12): 103-109.

[14]	Yue-lei FAN,Jiao LU,Da-ming CHEN,Kai-yun MAO. Strategies for Stem Cell Patent Evaluation and Patent Transfer and Transformation[J]. China Biotechnology, 2019, 39(1): 99-106.

[15]	Ping ZHAO,Bo ZHANG,Xue-zhao WANG. Patent Situation Analysis in Agricultural Biotechnology Field[J]. China Biotechnology, 2018, 38(8): 100-107.

Viewed

Full text

Abstract

Cited

Shared

Discussed